MapLight Therapeutics, Inc. (MPLT) stock
Close on Nov 12, 2026Market cap $327.89MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $327.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.94
- Dividend yield
- –
- Free cash flow yield
- -53.41%
Fundamentals
- Net income
- -$229.83M
- EPS, diluted
- -$18.56
- Free cash flow
- -$175.12M
- Book value per share
- $7.67
- Diluted shares
- 45M
Trading
- Next earnings
- Dec 3, 2026 (estimated, before the open)
- Previous close
- $7.48
- Open
- $7.46
- Day's range
- $7.01 – $7.63
- Volume
- 266,220
- Average volume (20 days)
- 347,454
- Index membership
- Russell 2000 (since Dec 2025)
- 52-week range
- $6.06 – $40.43
- RSI (14 days)
- 38.2
- Volatility (1 year)
- 112.9%
- Relative volume
- 0.37×
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MPLT | S&P 500 | Difference | MPLT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.8% | -2.7% | −15.1 pts | ||
| 3 months | -37.9% | -1.7% | −36.1 pts | ||
| Year to date | -59.7% | +11.9% | −71.6 pts | ||
| 1 year | -51.1% | +12.0% | −63.1 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MapLight Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Update
About MapLight Therapeutics
Pharmaceutical Preparations
MapLight Therapeutics is a clinical-stage biopharmaceutical company that develops circuit-specific therapies for debilitating central nervous system disorders. The company operates a discovery platform to identify neural circuits causally linked to diseases and target those circuits for therapeutic modulation. Its lead product candidate is ML-007C-MA, a fixed-dose combination combining a muscarinic agonist with a peripherally acting anticholinergic agent. Its development programs serve individuals suffering from psychiatric and neurological conditions, specifically patients with schizophrenia and Alzheimer's disease psychosis.
Company profile, executives and historyMapLight Therapeutics stock: common questions
What is MapLight Therapeutics's stock price?
MPLT closed at $7.07 on Nov 12, 2026, down 5.48% on the day. Over the past 52 weeks it traded between $6.06 and $40.43.
What is MapLight Therapeutics's market cap?
MapLight Therapeutics was worth $327.89M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MPLT's P/E ratio?
MapLight Therapeutics lost money over fiscal 2025 (diluted EPS -$18.56), so it has no meaningful P/E ratio.
Does MapLight Therapeutics pay a dividend?
No. MapLight Therapeutics has not paid a cash dividend over the last twelve months.
When does MapLight Therapeutics report earnings next?
MapLight Therapeutics is expected to report Q3 FY2026 results on Dec 3, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MPLT stock performed over the past year?
Including dividends, MPLT returned -51.1% over the past year, against +12.0% for the S&P 500.
Who are MapLight Therapeutics's competitors?
Companies most similar to MapLight Therapeutics by business, industry and size include NERV, RAPP, ANRO, CRVO, IGC.
See a number that looks wrong?